1. Scrip

Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear

 
• By Jessica Merrill

The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.

Hantson_Ludwig_1200x675
Alexion CEO Ludwig Hantson

Alexion Pharmaceuticals Inc.’s new CEO Ludwig Hantson will need to refocus the rare disease specialist onto a steady growth track after the company's recent missteps. Alexion announced the appointment of Hantson, formerly Baxalta Inc.'s CEO, on March 27.

Hantson succeeds David Brennan, who stepped in on an interim basis in December after former CEO David Hallal resigned for “personal reasons” amid an audit investigation related to sales of the company’s blockbuster Soliris (eculizumab)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.